Introduction
Per-and polyfluoroalkyl substances (PFAS) and surfactants and polymers made with the aid of PFAS have been widely used in industrial and commercial applications (Buck et al., 2011) . There have been two main PFAS production processes: electrochemical fluorination and telomerization. Polyfluoroalkyls have the potential to be transformed under abiotic or biotic conditions to perfluoroalkyls. PFAS are chemically and thermally stable compounds because of their strong C-F bonds. The perfluoroalkyl (C n F 2n+1 -) moiety provides hydrophobic and lipophobic properties. Perfluoroalkyl carboxylic acids with 7 or more perfluorinated carbons and perfluoroalkane sulfonates with 6 or more perfluorinated carbons are considered to be 'long-chain' perfluoroalkyls. Perfluorooctanesulfonate (PFOS, C 8 F 17 SO 3 -) and perfluorooctanoate (PFOA, C 7 F 15 CO 2 -) are the most frequently reported and highest PFAS concentrations measured in the blood (serum/plasma) of the general population. PFAS commercial use has included stain and soil repellant applications for fabrics, carpets, and leather and for grease-proof food-contact paper (Buck et al., 2011; Butenhoff et al., 2006) . Surfactant applications also included fluoropolymer processing aids (e.g., ammonium perfluorooctanoate used in polytetrafluoroethylene (PTFE) production), aqu-eous film-forming foams (AFFF) used to extinguish major hydrocarbon fires, acid-mist suppression in metal plating, incorporation in hydraulic fluids used in aviation, chemically driven oil production, and photolithographic use in the semiconductor industry.
Human exposure to PFAS may occur via direct and indirect sources including food, drinking water, consumer products, household dust, and ambient air (D'eon and Mabury, 2011) . Human exposure to PFOS or PFOA through one or more exposure pathways is considered direct exposure. Indirect refers to exposure to one of their precursors with subsequent biotransformation to PFOS or PFOA.
In 2000, a major U.S. manufacturer (3M Company) announced a voluntary phase-out of PFOS and PFOS-related products as well as other long-chain PFAS including PFOA and perfluorohexanesulfonate (PFHxS) because analytical capabilities showed these persistent compounds could be detected at low levels in the environment and in humans . In 2006, the United States Environmental Protection Agency (EPA) announced a Product Stewardship agreement with 8 global manufacturing companies who pledged to reduce PFOA emissions and product content by 95% in 2010 and work towards its elimination by 2015 (US EPA, 2006) . Other important global regulatory activities occurred in Canada (Environment Canada, 2011) and Europe (European Parliament Directive, 2006) . PFOS was listed as a persistent organic pollutant (Annex B) by the Stockholm Convention (2009). The reporting of the widespread presence and persistence of PFAS in the environment has now resulted in more than 3000 environmental and health-related publications since the year 2000 (Lau, 2014) including Hansen et al.'s novel method to measure perfluorinated compounds, PFOS, perfluorooctanesulfonamide (FOSA), PFHxS, and PFOA at low (ng/mL) levels by using tissue (serum) extract with high performance liquid chromatography-negative ion electrospray tandem mass spectrometry (Hansen et al., 2001) .
The measurement of PFAS and their trends on a cross-sectional basis became the focus of two research investigations in the United States. In 2003, Olsen et al. (2003) initially reported concentrations of 7 PFAS in 645 American Red Cross adult blood donors (ages 20-69). These donors' bloods (sera) were collected in 2000 -2001 , Calafat et al. (2007 reported on 8 PFAS serum measurements from archived blood samples that were collected in 1999-2000 from the much larger Centers for Disease Control and Prevention (CDC) National Health and Nutrition Examination Survey (NHANES). Olsen et al. (2007a) then reported a preliminary study of 40 American Red Cross adult blood donors from Minneapolis-St. Paul, whose blood was collected in 2006, to suggest a decline in serum PFOS after the phase-out as well the study by Spliethoff et al. (2008) analyzing 110 blood spot composites from infants (n =2640) born in New York state. These preliminary observations were later confirmed by the American Red Cross (Olsen et al., 2008 (Olsen et al., , 2011 (Olsen et al., , 2012 and the NHANES CDC, 2017) PFAS biomonitoring studies.
Whereas only NHANES is a nationally representative sample of the U.S. general population, the American Red Cross study does offer, unlike NHANES, regional analyses based on the same six blood collection centers since the study's inception in [2000] [2001] . The purpose of this updated American Red Cross study was to extend these regional trend analyses through blood collected in 2015 for 13 PFAS compounds, including PFHxS, PFOS, and PFOA.
Materials and methods

Sample collection
In 2015, six American Red Cross blood centers collected a total of 616 plasma samples for analysis of 13 PFAS concentrations. Blood was obtained during June -August 2015. Five locations (Boston, Massachusetts; Hagerstown, Maryland; Los Angeles, California; Minneapolis-St. Paul, Minnesota; and Portland, Oregon) provided 10 samples per every 10-year age interval (20-29, 30-39, 40-49, 50-59, and 60-69) for each sex. The sixth location (Charlotte, North Carolina) provided 116 samples (12 samples per every 10-year age and sex interval). The only available demographic factors were age, sex, and location. Samples were similarly collected from the same six locations (but different donors) in 2000-2001 (n =645 serum samples), 2006 (n =600 plasma samples), and 2010 (n =600 plasma samples). Plasma and serum matrices provide comparable PFAS results (Ehresman et al., 2007) . The American Red Cross Biomedical Services Institutional Review Board approved this study.
Laboratory assay
The samples from 2006, 2010, and 2015 Table S1 . The analytical laboratory was blinded to the identities of all samples during analysis. Results were determined for 616 adult donor samples collected in 2015. Additionally, there were 120 laboratoryblinded samples used for quality assurance purposes: 60 randomly selected 2015 duplicate splits and 60 nonrandomly selected archived (−80°C) samples whose selection was based on a distribution of prior concentrations measured and sample volumes that remained in the archived tubes from the previous years (2000-2001 (n =20), 2006 (n =20) and 2010 (n =20)) for a total of 736 samples analyzed in this study. The validated analytical test method employing protein precipitation extraction and quantitation by liquid chromatography tandem mass spectrometry (LC-MS/MS) used for analysis of the 2015 American Red Cross study samples has been previously described (Harrington et al., 2017) . The analytical test method and quality control data for the study are in the Supplemental File.
Data quality
The American Red Cross sample-specific SRS recoveries for all study samples provided a measure of sample-specific accuracy and precision that compared well with the target analyte and SRS recoveries from control human plasma QCs, as shown in the supplemental file (Table  S2 ). Excellent average method accuracy (100% ± 7%) and precision (RSD < 15%) were demonstrated in control human plasma for the perfluorinated carboxylates and perfluorinated sulfonates, FOSA, and the SRSs. EtFOSAA and MeFOSAA had average accuracies of 83.9% and 83.8%, respectively. The data mean accuracy and precision for SRS recoveries for the 736 analyzed samples were 89.0% (8.8% Relative Standard Deviation (RSD)) for [1, 2, 3, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] (Table S2) .
Isomer quantification
While differences in relative response factors for branched and linear PFOS isomers have been observed for selected matrices or due to instrumentation conditions Riddell et al., 2009 ), the levels of linear and branched isomers can be inferred from visual observations of the LC-MS/MS chromatographic data when the proper instrument conditions are used. The PFOS isomer composition in the American Red Cross study samples was not characterized for each individual possible isomer, however, chromatographic results visibly indicated separation of branched isomer peaks from the linear isomer and analysis results suggested enrichment of the branched isomers for PFOS in several samples at > 50% branched isomer content relative to the branched isomer content of reference substance brPFOS at~30% (w/w). In contrast, the PFOA in the blood samples was observable as mostly linear isomer (< 5% branched). The quantitation of fortified mixed linear and branched reference materials in human plasma QCs, as brPFOS (30% branched) at 10 and 40 ng/mL, and brPFHxS (19% branched) and brPFOA (5% branched) at 2.5 and 10 ng/mL, demonstrated average recoveries for brPFOS, brPFHxS and brPFOA at 101%, 87.8% and 102%, respectively.
NIST SRM 1957 ANalysis Results
The National Institutes of Standards and Technology (NIST) standard reference material (SRM) 1957 (Keller et al., 2010) results are shown in the supplemental file (Table S3 
Data analysis
Measures of central tendency (e.g., geometric mean) pertinent to log-normally distributed data were used. Samples reported as < LLOQ (lower limit of quantitation) were estimated to be the LLOQ divided by the square root of two; however, geometric means were not calculated for several compounds (PFBS, EtFOSAA, FOSA, PFHxA, PFHpA, PFUnA, and PFDoA) because the number of samples reported as below LLOQ (ng/mL) was considered too high to provide a valid result. Those PFAS with large number of subjects (in parentheses) below LLOQ were PFBS: < 0.047 (339); < 0.023 (225) EtFOSAA: < 0.02 (91) To compare the means overall between 2000 -2001, 2006, 2010, and 2015 , while adjusting for age, sex, and location the general linear model with a logarithmic link function and normal error was specified as follows:
where PFAS is the analyte of interest, Location, Year, and Age are vectors indicating location, year of collection and age category, respectively. Sex is an indicator variable, and ε is a normally distributed error term with mean zero. The model was fit to 1000 bootstrap samples for each compound, and the maximum likelihood estimates of means were contrasted using two-sided 95% confidence intervals that were constructed using the bias corrected, accelerated bootstrap method (Efron and Tibshirani, 1993) . The bias-correction factor is derived by comparing empirical percentiles to bootstrap percentiles and acceleration is accomplished by partial jackknifing, a method of systematically resampling the data. A similar model, excluding location, was used for analysis by location. All the generalized linear models were fit using maximum likelihood in the S-Plus (S-Plus 7, ©Insightful Corporation, 2005) program "lm" and the bootstrap estimates were generated using the S-Plus program "bootstrap."
In order to minimize parametric assumptions in the estimation of upper percentiles of the population, the bias-corrected, accelerated bootstrap method with 3000 replications was used to generate confidence intervals around the empirical percentiles for plasma concentrations of the analyzed compounds. These analyses provided upper 95% confidence bounds on the tolerance limits (90th, 95th, and 99th percentiles) that represented the concentration of each perfluoroalkyl below which the stated proportion of the population is expected to be found. This same methodology was used to calculate these estimates in the prior years as previously reported (Olsen et al., 2003 (Olsen et al., , 2008 (Olsen et al., , 2011 (Olsen et al., , 2012 . 
Results
Quality assurance
Comparison of 2015 American Red Cross samples to prior collection years
In 2015, the age-, sex-, and location-adjusted geometric means were the following: PFHxS 0.86 ng/mL (95% confidence interval (CI) 0.81−0.92); PFOS 4.30 ng/mL (95% CI 4.11−4.50); PFOA 1.09 ng/ mL (95% CI 1.03−1.14); PFNA 0.43 ng/mL (95% CI 0.41-0.45); and PFDA 0.15 ng/mL (95% CI 0.14-0.16). Fig. 1a (PFOS) and 1b (PFHxS, MeFOSAA PFOA, PFNA, PFDA) show temporal trends for the age-, sex-, and location-adjusted geometric means for these American Red Cross studies. Table S4 provides the data. The percentage decline in these geometric mean concentrations from 2000 to 2015 were PFHxS (61%), PFOS (88%), PFOA (77%), PFNA (33%), and PFDA (50%). Only two time points are shown for MeFOSAA (2006 and 2015) in Fig. 1b In 2015, males had significantly (p < 0.01) higher geometric mean concentrations than females for PFHxS (1.16 ng/mL vs. 0.65 ng/mL), PFOS (5.32 ng/mL vs. 3.52 ng/mL), and PFOA (1.23 ng/mL vs. 0.98 ng/mL). For most comparisons as shown by the non-overlapping 95% confidence intervals, significantly higher geometric mean concentrations were observed in males compared to females for PFOS (Fig. 2a) , PFHxS (Fig. 2b) , and PFOA (Fig. 2c) for each 10-year age group by the collection year. These trends were not as apparent for PFNA and PFDA. (See supplemental file Table S5 for the data.) The LLOQs, percentiles, and unadjusted geometric means for all sampling years and PFASs are presented in supplemental file Table S6 (see footnotes a-d of Table S6 for LLOQs.
Age-and sex-adjusted geometric mean temporal trends for each location are presented in Fig. 3 for PFOS (Fig. 3a) , PFHxS (Fig. 3b) , and PFOA (Fig. 3c) . Likewise, Fig. 4a -c show these trends for MeFOSAA, PFNA, and PFDA, respectively, for these six American Red Cross blood collection centers. (See supplemental file Table S7 for the locationspecific age-and sex-adjusted perfluoroalkyl geometric mean data and Table S8 for the unadjusted data).
G.W. Olsen et al. Environmental Research 157 (2017) 87-95 A possible explanation for the higher age-and sex-adjusted mean plasma perfluoroalkyl concentrations in the Charlotte location may be from potential exposures to PFAS commercial applications that occurred in the historic textile and apparel industry that was situated in the southwest region of North Carolina (Key industries, 2016) . This region's textile and apparel industry declined in the 1990s. As part of their analysis of the third U.S. EPA Unregulated Contaminant Monitoring Rule (UCMR3) municipal water sample data collected between 2013 and 2015, Hu et al. (2016) reported higher PFAS concentrations in the Raleigh to Fayetteville region of North Carolina, located approximately 200 km northeast of Charlotte. These researchers found UCMR3 areas to have higher PFAS water concentrations due to greater percentages of industrial sites, military fire training areas, and wastewater treatment plants. Table 1 provides estimates for the 90th, 95th, and 99th tolerance limits along with their bias-corrected upper one-sided confidence limit (bound) for 2000-2001, 2006, 2010, and 2015 . For PFOS the 90th, 95th, and 99th tolerance limits in 2015 were 9.6, 11.6, and 18.7 ng/mL with their 95% confidence limits calculated at 10.3, 13.2, and 22.0 ng/ mL, respectively. Similar in magnitude to the percentage change in the geometric means between 2000-2001 and 2015, the percentage decline (in parentheses) of the estimates of the 95th percentile in this 15 year trend analysis were PFOS (88%), PFHxS (63%), and PFOA (73%). Because the calculation of the upper tolerance limits in these analyses is not influenced by the values below LLOQ, it could be calculated that there was a 92% decline in MeFOSAA at the 95th percent tolerance limit between 2000-2001 and 2015 . Fig. 5a (PFOS) and 5b (PFHxS, PFOA) provide trends for the geometric means (95% CI) for the American Red Cross series of studies and NHANES by year of blood collection. An approximate population halving-time of 4.6 years for PFOS was estimated for the geometric mean serum/plasma concentrations the American Red Cross studies between 2000-2001 and 2015 that had been also estimated previously through the 2010 collection year (Olsen et al., 2012) . This estimate is similar to the geometric mean serum elimination half-life of 4.8 years (95% CI 4.0-5.8) for PFOS that was reported in a 5-year longitudinal study of 26 manufacturing production retirees (Olsen et al., 2007b) .
Discussion
The percentage concentration declines of PFOS and PFOA concentrations observed in these American Red Cross adult blood donors is similar to those being reported in other non-representative sampling studies being conducted in other countries including Germany (Yeung et al., 2013a (Yeung et al., , 2013b , Sweden (Glynn et al., 2012; Gebbink et al., 2015a) , and Australia (Toms et al., 2014; Eriksson et al., 2017) . Although percentage declines may be similar, absolute concentrations Fig. 1 . Age-, sex-, and location-adjusted geometric mean (with 95% confidence intervals) PFOS (Fig. 1a) and PFHxS, MeFOSAA, PFOA, PFNA, and PFDA (Fig. 1b) serum (2000) (2001) and plasma (2006, 2010, and 2015) concentrations (ng/mL), American Red Cross adult blood donors, 2000−2015. Fig. 2 . Geometric means (with 95% confidence intervals) by age and sex, for PFOS (Fig. 2a) , PFHxS (Fig. 2b) and PFOA (Fig. 2c) , American Red Cross adult blood donors, 2000−2015.
G.W. Olsen et al. Environmental Research 157 (2017) [87] [88] [89] [90] [91] [92] [93] [94] [95] may differ due to past and present potential exposures, time periods, and population studied. For example, the German studies (Yeung et al., 2013a; 2013b) collected samples through 2009 with few samples analyzed for any year. The Swedish studies were collected through 2010 (Glynn et al., 2012) and 2012 (Gebbink et al., 2015a ) but represented primparous women who provided serum samples in the 4th week after delivery of an infant. Pregnancy and lactation would factor into measured PFAS concentrations. During this same time period, the manufacture of PFOS and other PFAS-related products rapidly expanded in China resulting in higher serum concentrations of the Chinese population, particularly those residing in the eastern and coastal cities where segments of the fluoropolymer industry can be found that includes textiles, paper making, and electroplating . Thus, PFAS trend comparisons between populations should proceed cautiously. Diet has been considered a major source of perfluoroalkyl exposure (Domingo, 2012; Domingo and Nadal, 2017) . The European Food Safety Authority (EFSA, 2012) reported PFASs were often found in fish, seafood, meat, and meat byproducts (especially liver). EFSA estimated the tolerable daily intake (TDI) for PFOS and PFOA among high consumers was less than 6.7% and 0.5% of the TDI, respectively. Among adults, the 95th percentile exposure for PFOS ranged from (Fig. 3a) , PFHxS (Fig. 3b) , and PFOA (Fig. 3c) for serum (2000−2001) and plasma (2006, 2010, and 2015) concentrations (ng/mL) for six regional American Red Cross adult blood donor centers, 2000−2015. Fig. 4 . Age-and sex-adjusted geometric mean (95% confidence interval) MeFOSAA (2006 MeFOSAA ( , 2015 (Fig. 4a) , PFNA (Fig. 4b) , and PFDA (Fig. 4c) serum (2000-2001) and plasma (2006, 2010, 2015) concentrations (ng/mL) for six regional American Red Cross adult blood donor centers.
G.W. Olsen et al. Environmental Research 157 (2017) 87-95 and PFHxS found in milk, eggs, and farmed rainbow trout with the latter two dietary items likely due to contamination declines in the feed offered to hens and farmed fish. In the United States, Christensen et al. (2017) recently reported an association between serum perfluoroalkyl measurements and self-reported fish consumption data in 4 NHANES cycles of data collected between 2007 and 2014. They found associations between MeFOSAA, PFNA, and PFDA with self-reported fish consumption in the 30 days prior to the blood collection. Several PFASs were also associated with shellfish, including PFOS. Such meals, however, were reported infrequently (median of 1.2 fish meals and 0.14 shellfish meals per month) in these NHANES populations. Zhang et al. (2010) collected meat and egg samples from a wide geographical distribution of 17 cities in 15 provinces in China. Assuming values ½ the lower limit of quantitation, they estimated daily intake for PFOS was 8.8-15 ng/d and 255-577 ng/d for PFOA. Most dietary exposure to PFOS was from fish and seafood whereas meat was a major source for PFOA. Indirect exposures from commercial PFOS-based products are also significant sources of exposure to PFOS as higher molecular weight derivatives have the potential to degrade to PFOS (D'eon and Mabury, 2011) . These included the precursors MeFOSAA and EtFOSAA that were measured in this study. For these two compounds, geometric means could not be determined in 2015 due to the high proportion of samples below the LLOQ as compared to prior years. For example, the 95th percentile of PFOS, MeFOSAA, and EtFOSAA concentrations in 2000-2001 were 75.1 ng/mL, 4.8 ng/mL, and 6.5 ng/mL, respectively (supplemental file Table S6 ). In 2015, these 95th percentiles were 8.6 ng/mL, 0.4 ng/mL, and 0.05 ng/mL, respectively, suggesting MeFOSAA and EtFOSAA may have been important precursors of exposure in the past given the decline of PFOS. Martin et al. (2010) recommended more precise analytical methods might distinguish directly manufactured PFOS from that biotransformed from PFOSprecursors. They reported non-racemic PFOS body burdens of the α-branched PFOS (1m-PFOS, i.e., C 6 F 13 CF(CF 3 )SO 3 -) could be a biomarker of significant exposure to PFOS-precursors. Others in Japan (Miyake et al., 2007) and China (Yeung et al., 2008; Yeung and Mabury, 2016) (Fig. 5a ) and PFHxS and PFOA (Fig. 5b) geometric mean serum/plasma concentrations (with 95% confidence intervals), 2000−2015.
G.W. Olsen et al. Environmental Research 157 (2017) 87-95 have estimated the percent of extractable organic fluorine that is not accounted for in PFAS analyses as this percentage would reflect other unknown PFAS precursors. Depending on the occupational or nonoccupational population studied, the unaccounted fraction reported by these investigators ranges between 30% and 70%. Neither NHANES nor the American Red Cross studies have reported total organic fluorine measurements.
In 2006 While PFOS and PFOA concentrations have declined in the United States general population and elsewhere and extensive research of levels of PFAS in environmental matrices has been published (Houde et al., 2011; Reiner and Place, 2014) , significant gaps remain in the reporting of general environmental trends and correlation to human exposure levels. Recent reviews cite the complexity of environmental fate of PFAS and the shortcomings in the scientific knowledge relating to transport, partitioning, and the PFAS transformation processes after their release into the environment (Riget et al., 2013; Ahrens and Bundschuh, 2014; Richardson and Kimura, 2014; Miralles-Marco and Harrad, 2015) . Nevertheless, site-specific environmentally-related exposures have been identified that could result in local communities with higher serum PFOS, PFHxS, PFOA, and other PFAS concentrations than observed in the general population. These affected communities tend to reside near: 1) industrial plants that used PFOA in fluoropolymer production activities (Frisbee et al., 2009 ); 2) military or commercial airports that have used aqueous film forming foam for emergency and fire training needs (Place et al., 2012 , Weiss et al., 2012 as well as other sporadic industrial accidents including railcar derailments (Munoz et al., 2017) ; 3) landfills where PFAS leachate can occur (Busch et al., 2010; Lang et al., 2017) and 4) agricultural fields where biosolids from waste water treatment plants have been applied (Skutlarek et al., 2006; Wilhelm et al., 2008; Lindstrom et al., 2011; ATSDR, 2013) . For these exposures, environmental release into surface and/or ground water can result in PFAS to be found in drinking water sources. Exposure reduction activities (e.g., installation and routine replacement of granulated activated charcoal (GAC) filters into a municipal water system) have been effective at reducing long chain PFAS water concentrations which has resulted in lowered serum perfluoroalkyl (e.g., PFOS, PFOA) concentrations in affected populations (Bartell et al., 2010; Minnesota Dept. Health, 2015) .
The U.S. EPA recently issued a lifetime drinking water health advisory of 0.07 μg/L for PFOS, PFOA, or their sum (U.S. EPA, 2016a EPA, , 2016b . Other national and state assessments based on drinking water, as well as dietary exposure guidelines, for PFOS and PFOA have been reviewed by Butenhoff and Rodricks (2014) . For example, The German Drinking Water Commission of the Federal Environment Agency has issued a guideline of 0.1 μg/L for PFOA and 0.1 μg/L for PFOS (Germany, 2016) . The Canadian Federal-Provincial-Territorial Committee on Drinking Water has a proposed guideline of a maximum acceptable value of 0.2 μg/L for PFOA (Canada, 2016) . Both the American Red Cross and the NHANES investigations continue to indicate a weak decline in the geometric mean for PFHxS. Because PFHxS appears to be slowly eliminated from human serum (Olsen et al., 2007b) and has often been measured in household dust along with other PFASs (Kato et al., 2009; Fraser et al., 2013) , the question arises as to what proportion of this slow decline in PFHxS concentrations is a function of its pharmacokinetics versus background exposures to consumer household or office applications including dust (Beesoon et al., 2012) , through the diet (EFSA, 2012), drinking water (MDH 2017), or other possible exposures (Favreau et al., 2017) . The long but imprecise serum elimination half-life of PFHxS in humans, reported as a geometric mean of 7.3 years (95% CI 5.8−9.2), is likely the primary contributor to this observation.
Replacement PFAS chemistries that have been introduced into the marketplace and measured in this study were two shorter-chain PFAS (PFBS, PFHxA) that are considered to have more favorable environmental and biological properties than longer chain PFASs (Buck et al., 2014) . Others have expressed reservations about the alternative shorter chain PFAS (Scheringer et al., 2014; Blum et al., 2015) including whether these compounds will become ubiquitous in the environment, whether they can be filtered from affected drinking water, and the formation of persistent terminal transformation products in the environment. For some manufacturers, their focus has centered on the production of PFBS and perfluorobutanesulfonyl-related products. The present study showed only 8.4% of the 2015 American Red Cross samples had a quantifiable serum PFBS concentration (range LLOQ -4.2 ng/mL). The 95th percentile was 0.02 ng/mL. The NHANES 2013-2014 data reported the 95th percentile for PFBS at below the level of detection (0.1 ng/mL). PFBS has been estimated to have a serum elimination half-life approximating 26 days (range 13-46 days) in the human with the kidney the primary elimination pathway (Olsen et al., 2009 ). Other companies have commercialized the 6:2 fluorotelomer and its precursor products as an alternative to the 8:2 fluorotelomer that can metabolize to PFOA . The 6:2 fluorotelomer can metabolize to PFHxA. There were 3.3% of the 2015 American Red Cross samples that had a quantifiable PFHxA concentration (range LLOQ -0.27 ng/mL). The serum elimination half-life of PFHxA has been estimated to be 32 days (range 14 -49 days) (Russell et al., 2013) .
Study limitations included the fact that the American Red Cross studies, as well as NHANES, are both a series of cross-sectional investigations. Individuals were not followed longitudinally as this type of study design is infrequently reported (Nøst et al., 2014; Stubleski et al., 2016) . The study's laboratory analytical methods improved over time especially with the introduction of labeled standards and now this validated single injection method; thus greater analytical variation likely existed in the earlier measurements. Other classes of perfluoroalkyl precursors were not analyzed in this study including the polyfluoroalkyl phosphate diesters (diPAPs) that have been used as food packaging grease protectants and fluorotelomer sulfonic acids that have been used as wetting or foaming agents. These PFAS have been measured in human serum at low pg/mL levels (Lee and Mabury, 2011; Gebbink et al., 2015b; Eriksson et al., 2017) . The declining trends observed in these American Red Cross adult blood donors should not be extrapolated to other country trends without consideration of these nations' potential direct and indirect exposure scenarios.
Conclusion
Age-and sex-adjusted geometric mean serum (2000) (2001) and plasma (2006, 2010, 2015) concentrations (ng/mL) were compared across six American Red Cross blood collection centers. The results indicate a continued decline of PFHxS, PFOS, and PFOA concentrations in American Red Cross adult blood donors. For the shorter chain perfluoroalkyls PFBS and PFHxA that were measured in 2015, the majority of samples were below the lower limit of quantitation.
